retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide
Pay in 4 interest-free payments of $5.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19












00226-8/asset/34cd96f1-6db7-4717-834c-4ef722d58de8/main.assets/gr3_lrg.jpg)

00213-0/asset/3bf08982-433a-4e78-933c-d49e6ac25024/main.assets/gr1_lrg.jpg)














